A detailed history of Vestal Point Capital, LP transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Vestal Point Capital, LP holds 250,000 shares of ASND stock, worth $34.7 Million. This represents 2.83% of its overall portfolio holdings.

Number of Shares
250,000
Previous 750,000 66.67%
Holding current value
$34.7 Million
Previous $102 Billion 63.51%
% of portfolio
2.83%
Previous 7.63%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$113.0 - $153.43 $56.5 Million - $76.7 Million
-500,000 Reduced 66.67%
250,000 $37.3 Billion
Q2 2024

Aug 14, 2024

BUY
$121.07 - $153.67 $27.2 Million - $34.6 Million
225,000 Added 42.86%
750,000 $102 Billion
Q1 2024

May 13, 2024

SELL
$123.45 - $159.4 $12.3 Million - $15.9 Million
-100,000 Reduced 16.0%
525,000 $79.4 Billion
Q4 2023

Feb 13, 2024

BUY
$86.1 - $127.36 $53.8 Million - $79.6 Million
625,000 New
625,000 $78.7 Billion

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.75B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Vestal Point Capital, LP Portfolio

Follow Vestal Point Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vestal Point Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Vestal Point Capital, LP with notifications on news.